Skip to content

Positive valence system-focused cognitive behavioral therapy using virtual reality on depression: A feasibility study

Positive valence system-focused cognitive behavioral therapy using virtual reality on depression: A feasibility study - PoCot-VR

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040864
Enrollment
12
Registered
2020-06-23
Start date
2020-06-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Positive valanced system-focused cognitive behavioral therapy treats anhedonia and is delivered for 60 minutes once a week, eight times during 11 weeks. Patients will use virtual reality technology to

Sponsors

National Center for Cognitive Behavior Therapy and Research, National Center Hospital of Neurology and Psychiatry
Lead Sponsor
JOLLY GOOD Inc.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Having at least mild symptoms of depression (Scoring 11 or higher on BDI-II) 2. Between 18 and 64 years old

Exclusion criteria

Exclusion criteria: (a) Current psychotic disorders at baseline assessed by the Mini-International Neuropsychiatric Interview (MINI) (b) Current manic episodes at baseline assessed by MINI (c) Currently severe substance use disorders at baseline assessed by MINI (d) Serious suicidal ideation at baseline assessed by MINI (e) Medical devices that impair the functionality of the VR device (a pacemaker, hearing aid, defibrillator, implantable medical devices, etc.) (f) No permission from the doctor to use the VR device (g) Other problems that become significant obstacles when administering cognitive behavior therapy and implementing the VR deice

Design outcomes

Primary

MeasureTime frame
Beck Depression Inventory-II (BDI-II) at week 12

Secondary

MeasureTime frame
Japanese version of the Snaith-Hamilton Pleasure Scale (SHAPS) at week 12 Anhedonia sub-scale of BDI-II at week 12

Countries

Japan

Contacts

Public ContactToshitaka Hamamura

National Center Hospital of Neurology and Psychiatry National Center for Cognitive Behavior Therapy and Research

toshitaka-hamamura@umin.ac.jp+81-42-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026